JLJara Llenas-García

Jara Llenas-García

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jara Llenas-García has a total of 829 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    First-Line Antiretroviral Regimens and Risk of Incident Hypertension in People With HIV: A 15-Year Cohort Study

    by José I Bernardino, C Busca, L Serrano, A de Gea-Grela, M M Arcos-Rueda, L Martin-Carbonero, M L Montes, R Montejano, J Llenas-García, R Mican, et al.

    Background: People with HIV (PWH) face a growing burden of cardiovascular disease. Integrase strand transfer inhibitors (INSTIs) have been linked to weight gain and possibly hypertension, but head-to-head data among contemporary regimens are scarce, and few studies analyze older and modern regimens together. We evaluated the incidence of hypertension in antiretroviral therapy (ART)-naive PWH initiating Spanish guidelines-recommended first-line regimens since 2009. Methods: This study evaluated a retrospective cohort of ART-naive adults initiating first-line regimens from 2009 to 2024, grouped into non-nucleoside reverse transcriptase inhibitor (NNRTI), INSTI, and boosted protease inhibitor (PI)-based classes. Incident hypertension was defined by a composite of clinical diagnosis, antihypertensive initiation, or 2 consecutive measurements ≥ 140/90 mmHg. Time to hypertension was analyzed using Kaplan–Meir methods and Cox regression, with a prespecified INSTI subanalysis. Results: Among 1134 participants (median age 34.1 years; 89.8% male), 205 (18.1%) developed hypertension over a median of 135.9 weeks (incidence 4.9/100 person-years). Hypertension-free survival differed by class (log-rank P = .005); INSTI-based ART was independently associated with higher risk than NNRTIs (adjusted HR 1.61; 95% CI 1.20–2.17). Within the INSTI subgroup (n = 437; incidence 7/100 person-years), 5-year cumulative hypertension ranged from 9% (EVG/c/FTC/TAF) to 37% (dolutegravir-based); dolutegravir-based regimens carried a >2-fold adjusted hazard versus EVG/c/FTC/TAF. Higher body mass index was independently predictive but did not abolish this signal. Conclusions: In ART-naive PWH, INSTI-based regimens were associated with a higher incidence of hypertension than NNRTI-based regimens, whereas the comparison with PI-based regimens was not statistically significant. Dolutegravir-containing regimens were independently associated with incident hypertension supporting systematic blood pressure surveillance and further comparative studies.

  • Neurocysticercosis as a surgical surprise: lessons from a solitary lesion mimicking primary brain neoplasm in a non-endemic setting

    by Lucía Platero, Graciela Rodríguez-Sevilla, Maríaisabel Esteban-Rodríguez, Begoña Marín, Jorge Zamorano, Beatriz Díaz-Pollán, Rosa de Miguel, Marta Díaz-Menéndez, Jara Llenas-García

  • Open Access

    Cost-effectiveness of lenacapavir versus tenofovir disoproxil fumarate plus emtricitabine for pre-exposure prophylaxis to prevent HIV-1 transmission in gay, bisexual, and other men who have sex with men in Spain

    by Philip Erick Wikman-Jorgensen, Carlos Iniesta, Marta Ruiz-Algueró, Vicente Estrada, Federico Pulido, Jose A. Perez-Molina, Jara Llenas-García

  • Open Access

    Effect of Non-nucleoside Resistance-Associated Mutations on the Effectiveness of Long-Acting Cabotegravir + Rilpivirine Therapy: Insights From the Real-World RELATIVITY Cohort

    by David Rial-Crestelo, Jara Llenas-García, Carmen Hidalgo-Tenorio, Jesús Troya García, María José Galindo Puerto, María Remedios Alemán Valls, Miguel Torralba González de Suso, Luis Buzón, Alberto Díaz de Santiago, Adrián Rodríguez, et al.

    Background: The impact of pre-existing non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations (RAMs) on the effectiveness of long-acting (LA) cabotegravir (CAB) and rilpivirine (RPV) remains poorly defined, particularly for mutations like K103N that do not directly compromise RPV susceptibility (non-RPV NNRTI RAMs). Methods: This observational substudy within the Spanish RELATIVITY cohort included people with HIV (PWH) who switched to CAB + RPV LA before 2025. We compared virologic outcomes between those with non-RPV NNRTI RAMs and a reference group without NNRTI/INSTI-RAMs or prior NNRTI-based virologic failure (VF). An additional subgroup with RPV-associated RAMs was also analyzed. Confirmed virologic failure (CVF) was defined as 2 consecutive viral loads ≥ 200 copies/mL or 1 ≥500 copies/mL. Results: Among 1358 participants, 83 (6.1%) harbored non-RPV NNRTI RAMs (47 with K103N) and 1247 served as the reference group. After a median follow-up of 16.7 months, CVF rates were similar between the non-RPV NNRTI RAMs group and the reference group (1.2% vs 0.8%; HR: 1.39; 95% CI: 0.18–10.84; P = .755). No significant differences were observed in viral blips (6% vs 8.2%; P = .481). Notably, in the subgroup of 28 participants with RPV-associated RAMs (including 5 with high-level resistance), no CVFs occurred over a median of 13.5 months. Conclusions: In a real-world setting, CAB + RPV LA demonstrated high effectiveness in PWH with pre-existing NNRTI RAMs that do not compromise RPV susceptibility, including K103N. While no failures were seen in those with RPV-associated RAMs, these results should be interpreted with caution due to the small sample size.

  • Open Access

    Effectiveness and Persistence of Long‐Acting Injectable Cabotegravir and Rilpivirine in Migrant Individuals Living With HIV in Spain: Substudy of the RELATIVITY Cohort

    by Jara Llenas‐García, María del Mar Arcos Rueda, Ruth Calderón Hernaiz, Roberto Pedrero Tomé, Otilia Bisbal Pardo, Mariano Matarranz, Miguel Torralba, María José Galindo Puerto, Adrián Rodríguez, María Peñaranda Vera, et al.

    Introduction: Migrants living with HIV often face high mobility, vulnerability and limited baseline information on HIV‐1 genotype or treatment history. We aimed to assess the effectiveness and persistence of long‐acting injectable cabotegravir and rilpivirine (LAI CAB+RPV) among migrants in Spain. Methods: This multicentre cohort study across 58 Spanish hospitals included virologically suppressed adults switching to CAB+RPV LAI before January 2025. Data collection started in June 2023. Baseline characteristics and outcomes were compared by migrant status, and multivariate Cox proportional hazards regression models were fitted to assess factors associated with virological failure (VF) and discontinuation. Propensity score matching (PSM) by gender, age, known genotype and prior VF was employed to control for confounding. Results: Of 3135 participants, 951 (30.3%) were migrants, predominantly from Latin America. Median follow‐up was 13.8 months (interquartile range 8.91–19.1). VF occurred in 0.9% of migrants versus 0.5% of Spanish‐born individuals (odds ratio 1.89, 95% confidence interval [CI] 0.69–5.03; p = 0.22). In adjusted models, migrant status showed a non‐significant trend towards higher VF (adjusted hazard ratio [aHR] 2.16, 95% CI 0.89–5.22; p = 0.079). At 12 months, 95.8% of migrants (461/481) persisted on LAI CAB+RPV treatment versus 98.3% of Spanish‐born individuals (1348/1372) ( p = 0.005). Discontinuation due to any adverse event was more frequent in migrants (3.3% vs. 1.8%). Migrant status was significantly associated with discontinuation due to both local (aHR 2.63, 95% CI 1.33–5.26; p = 0.005) and systemic adverse events (aHR 3.33, 95% CI 1.45–7.69, p = 0.005). In the PSM cohort ( n = 932 per group), migrant status was independently associated with increased risk of VF (aHR 3.51, 95% CI 0.95–12.98, p = 0.045) and discontinuation due to systemic adverse events (aHR 2.88, 95% CI 1.01–8.17, p = 0.047). Conclusions: Nearly one‐third of participants switching to LAI CAB+RPV were migrants. While VF was rare overall, migrants had a significantly higher risk of treatment discontinuation, partly driven by adverse events. These findings highlight the need for closer monitoring and tailored strategies to optimize persistence with LAI regimens in migrant populations.


  • Open Access

    AdMiRE study: Development and validation of a WHO-aligned tool to assess healthcare access and antibiotic use among migrant populations in Europe—a multicountry Delphi and psychometric study on behalf of ESGITM group

    by Giacomo Guido, Aula Abbara, Muhammad Asaduzzaman, Ferenc Balazs Farkas, Kader Diabate, Alexandre Duvignaud, Ville Holmberg, Sorie Ibrahim Conteh, Sofia Jordão, Roberta Papagni, et al.

  • Community-Based Screening for HIV and Viral Hepatitis Using Dried Blood Spots in a Migrant Population in Spain: The HEPINMIGRA Study

    by Jara Llenas-García, Miriam Navarro, Maria Paz Ventero, Pilar Juan Cuevas, Juan Carlos Rodríguez, José Manuel Ramos-Rincon, Ana López Amoros, Ana Lucas Dato, Belén Martínez López, María García López, et al.

    Migrant populations face a disproportionate risk of undiagnosed HIV and viral hepatitis, posing a major challenge to elimination goals. The HEPINMIGRA study evaluated the acceptability, feasibility, and effectiveness of an integrated community-based screening program for migrants in Alicante, Spain. Between March 2024 and February 2025, nine outreach campaigns were conducted in community settings with the support of intercultural mediators. Screening was performed using finger-prick dried blood spots. Among 535 attendees, 529 migrants were screened (acceptance rate 98.9%). Participants had a median age of 39 years, 56.1% were male, and 77.9% were of African origin. Seroprevalence was 1.1% for HIV (95% CI: 0.4-2.3%), 0.6% for HCV (95% CI: 0.1-1.6%), and 4.5% for HBsAg (95% CI: 2.9-6.6%). Although most individuals with positive results were successfully contacted and linked to care, treatment initiation rates were low. Community-based DBS screening was highly feasible and effective for case detection, but major gaps were identified in linkage to care and treatment initiation.


  • Long‐acting cabotegravir and rilpivirine in people with HIV and obesity: Real‐world outcomes from the RELATIVITY cohort

    by Jesús Troya, Rafael Mican, María José Galindo, Otilia Bisbal, Lucía Romero, Miguel Torralba, Luis Buzón‐Martín, Sara de la Fuente, Francisco Fanjul, Adrián Rodríguez, et al.

    Introduction: Long‐acting injectable cabotegravir and rilpivirine (LAI CAB + RPV) is a well‐established regimen for people with HIV (PWH) that offers high efficacy and tolerability. However, data are limited for obese individuals with a body mass index (BMI) ≥ 30 kg/m 2 , which may represent a potential risk factor for virologic failure (VF). Methods: We conducted a multicentre, ambispective study (RELATIVITY cohort, Spain) of virologically suppressed PWH with BMI ≥ 30 kg/m 2 who switched to LAI CAB + RPV. This study characterized this population and evaluated the factors associated with virologic outcomes, tolerability and adherence using Kaplan–Meier analysis. Results: Among the 3,203 individuals recruited in the RELATIVITY cohort, 57 were excluded due to detectable HIV RNA at the time of switching to LAI CAB+RPV, and 3,146 were finally included, all of whom had HIV RNA levels 2 and 2,374 had a BMI 2 . Obese participants were older (median age 48 vs. 45 years) and included a higher proportion of women (21.9% vs. 13.7%). Comorbidities included dyslipidaemia (36.7%), hypertension (22.9%), diabetes (11.6%), chronic lung disease (6.4%), MASLD (5.5%) and coronary disease (3.3%). The main reasons for switching included quality‐of‐life improvement (49.2%), patient requests (35.4%), and therapy simplification (26%). VF was rare, occurring in 1.1% of obese individuals and 0.6% of non‐obese participants over a median follow‐up of 13.8 months ( p = 0.284). Emergent resistance mutations were detected in 2/4 VF in obese participants. The discontinuation rate was low across all study groups. Among participants with obesity, local adverse events accounted for 1.9% of discontinuations, systemic adverse events for 0.8%, and other causes for 3.9% of discontinuations. In this subgroup, 72.9% of injections were administered using a 38‐mm needle. Injection adherence was excellent, with 83.1% of participants with obesity achieving full (100%) coverage and an additional 16.3% maintaining 90–99.9% coverage. Conclusions: In this real‐world cohort, LAI CAB + RPV was safe and effective in PWH with obesity, with comparable VF rates, tolerability, and adherence to participants without obesity. These findings support the use of LAI CAB + RPV across diverse PWH populations, including those with a BMI ≥ 30 kg/m 2 , and highlight its feasibility in PWH with multiple comorbidities.


  • Open Access

    Clinical and Epidemiological Characteristics of an Oropouche Virus Outbreak in Loreto, Peru (October 2024–March 2025)

    by Miguel Ángel Rojo-Pérez, Edgar A. Ramírez-García, Jara Llenas-García

    Oropouche virus (OROV) has emerged as a significant arboviral pathogen in South America, responsible for recurrent outbreaks of febrile illness. In the Loreto region of Peru, more than 600 cases were reported in 2024, markedly exceeding expected incidence rates. We conducted a retrospective observational study using clinical–epidemiological records of all RT-qPCR-confirmed cases of Oropouche fever from the Regional Health Directorate of Loreto between October 2024 and March 2025. A total of 100 confirmed cases were identified. The most frequent symptoms were fever (88%), headache (78%), and myalgia (72%). No atypical or neurological presentations were reported. No severe cases or deaths occurred. Eight patients required hospitalization, mainly due to severe abdominal pain, persistent vomiting, arthralgia, and pregnancy. Six pregnant women were identified; three experienced pregnancy complications, though no fetal malformations or miscarriages were observed. This outbreak represents a new OROV epidemic in the region, with fewer cases than in 2024 and predominantly mild clinical courses. Although outcomes were generally favorable, the occurrence of complications in pregnant women underscores the importance of continued molecular surveillance and targeted public health interventions.


  • A prospective assessment of the efficacy and durability of long-acting cabotegravir and rilpivirine in individuals with HIV in Spain (RELATIVITY study)

    by Luis Buzón-Martín, Maria Luisa Montes, Roberto Pedrero, María José Galindo, Mireia Santacreu-Guerrero, María Remedios Alemán, Miguel Torralba, Alberto Díaz de Santiago, Fran Fanjul, Adrián Rodríguez, et al.

    Background: Daily oral antiretroviral therapy (ART) has transformed HIV into a chronic, manageable condition, but it still poses psychological, logistical, and biological challenges. Long-acting injectable (LAI) cabotegravir plus rilpivirine provides an alternative for virologically suppressed individuals, reducing treatment fatigue, stigma, and daily dosing. While clinical trials have demonstrated efficacy and safety, real-world data remain limited. We assessed the effectiveness and safety of LAI cabotegravir plus rilpivirine in Spain. Methods: RELATIVITY is a 5-year, multicentre, ambispective, non-controlled cohort study. The primary endpoint was treatment effectiveness, defined as the proportion of patients discontinuing LAI therapy for any reason, including loss of virological suppression (HIV-RNA >50 copies/mL) during follow-up, regardless of formal failure criteria. Results: This interim analysis (cut-off: March 1, 2025) included 3203 patients from 58 Spanish hospitals; 57 were excluded due to detectable viral load at switch, leaving 3146 participants. Most were men (84.6%), with a median age of 45 years. Median time on ART before switching was 9.0 (5.0–15.0) years, and duration of viral suppression was 84.0 (36.0–132.0) months. Prior integrase inhibitor–based regimens were reported in 77.1%. Virological suppression was maintained in ≥96% through 23 months of follow-up. Overall, 6.4% (n = 199) discontinued, most frequently for injection-site reactions (n = 45), systemic adverse events (n = 29), or virological failure (n = 20). Conclusions: Interim results from the RELATIVITY cohort confirm high effectiveness and safety of LAI cabotegravir plus rilpivirine in Spanish clinical practice, consistent with randomized trial outcomes and real-world data. An extended follow-up will provide further insights.